EP2191831B1 - Modifying pirfenidone treatment for patients with atypical liver function - Google Patents

Modifying pirfenidone treatment for patients with atypical liver function Download PDF

Info

Publication number
EP2191831B1
EP2191831B1 EP09252572A EP09252572A EP2191831B1 EP 2191831 B1 EP2191831 B1 EP 2191831B1 EP 09252572 A EP09252572 A EP 09252572A EP 09252572 A EP09252572 A EP 09252572A EP 2191831 B1 EP2191831 B1 EP 2191831B1
Authority
EP
European Patent Office
Prior art keywords
pirfenidone
day
patient
liver function
grade
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP09252572A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2191831A1 (en
Inventor
Williamson Ziegler Bradford
Javier Szwarcberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41427890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2191831(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/428,393 external-priority patent/US7566729B1/en
Priority to PL11001414T priority Critical patent/PL2343070T3/pl
Priority to PL09252572T priority patent/PL2191831T3/pl
Priority to DK11001414.9T priority patent/DK2343070T3/en
Priority to EP12166074.0A priority patent/EP2500019B1/en
Priority to SI200930033T priority patent/SI2191831T1/sl
Priority to MEP-2011-113A priority patent/ME01189B/me
Application filed by Intermune Inc filed Critical Intermune Inc
Priority to EP11001414.9A priority patent/EP2343070B1/en
Priority to EP12166073A priority patent/EP2505199A1/en
Publication of EP2191831A1 publication Critical patent/EP2191831A1/en
Publication of EP2191831B1 publication Critical patent/EP2191831B1/en
Application granted granted Critical
Priority to CY20111100614T priority patent/CY1111595T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the disclosure relates generally to pirfenidone and uses for reducing adverse effects associated with the treatment of diseases and disorders. More particularly, the disclosure relates to pirfenidone and uses for reducing abnormal liver function associated with 5-methyl-1-phenyl-2-(1H)-pyridone ("pirfenidone”) therapy.
  • pirfenidone 5-methyl-1-phenyl-2-(1H)-pyridone
  • U.S. Pat. Nos. 3,974,281 , 4,042,699 , and 4,052,509 generally relate to pirfenidone administration.
  • Pulmonary fibrosis can be caused by a number of different conditions, including sarcoidosis, hypersensitivity pneumonitis, collagen vascular disease, and inhalant exposure.
  • Idiopathic pulmonary fibrosis IPF is a distinct entity, characterized by breathing difficulty, radiographic abnormalities, and progressive loss of lung function. It is invariably progressive, and carries a grave prognosis with a median life expectancy of 2-3 years.
  • Pirfenidone has been administered to IPF patients.
  • Raghu et al. (“Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study.” Am J Respir Crit Care Med 159:1061-1069, 1999 ) reported administration of pirfenidone. No adverse events in hematology or blood chemistry were noted.
  • Azuma et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.” Am J Respir Crit Care Med 171:1040-1047, 2005 ) describes administration of pirfenidone to a maximum of 1800 mg/day of pirfenidone, and reports a protocol for stepwise reduction and rechallenge with drug after an adverse event.
  • Abnormal liver function may manifest as abnormalities in levels of biomarkers of liver function, including alanine transaminase, aspartate transaminase, bilirubin, and/or alkaline phosphatase, and may be an indicator of drug-induced liver injury. See FDA Draft Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation, October 2007.
  • One aspect of the invention provides pirfenidone for administering a therapeutically effective dose of pirfenidone to a patient that has exhibited abnormal biomarkers of liver function according to the claims after pirfenidone administration for the treatment of fibrosis, e.g. idiopathic pulmonary fibrosis (IPF) as set out in the claims.
  • fibrosis e.g. idiopathic pulmonary fibrosis (IPF) as set out in the claims.
  • a patient is identified who exhibits a significantly abnormal level of one, two, three or more biomarkers of liver function, e.g. the level of a Grade 2 abnormality, after administration of an original full target dose of pirfenidone, e.g. 2400 mg/day or 2403 mg/day.
  • the dose of pirfenidone is reduced or discontinued until levels of the abnormal biomarkers approach or are within normal range, after which the pirfenidone is for administering to patients increasing doses of pirfenidone, up to the original full target dose.
  • the dose of pirfenidone is not reduced at all, but liver biomarkers continue to be monitored.
  • the pirfenidone is for administering to patients pirfenidone at a permanently reduced dose of 1602 mg/day.
  • original full target dose means the therapeutically effective dose approved by the U.S. Food and Drug Administration or a similar agency in a foreign country, optionally other than Japan.
  • the original full target dose is 2400 mg/day or 2403 mg/day pirfenidone, or 34 mg/kg/day (e.g. 33-35 mg/kg/day) according to the claims, or from 2200 to 2600 mg/day pirfenidone, or from 31 mg/kg/day to 37 mg/kg/day according to the claims.
  • the total daily dose is administered one, two or three times per day.
  • the invention provides pirfenidone for administering pirfenidone to a patient at doses of 2400 mg/day or 2403 mg/day after identifying that the patient has exhibited a liver function Grade 2 abnormality after pirfenidone administration.
  • the invention involve continuing the full target dose, e.g. of 2400 mg/day or 2403 mg/day, without temporarily discontinuing or reducing the dose.
  • the patient's biomarkers of liver function may continue to be monitored.
  • the invention involves (a) administering a dose lower than 2400 mg/day for a time period, e.g., one week, two weeks, three weeks, four weeks, one month, six weeks, or two months, followed by (b) administering a dose of 2400 mg/day or 2403 mg/day.
  • a time period e.g., one week, two weeks, three weeks, four weeks, one month, six weeks, or two months
  • the pirfenidone is temporarily discontinued before step (a).
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality as follows: (a) administering 1600 mg/day or 1602 mg/day pirfenidone for one week, or until the liver function biomarkers return to Grade 0 or Grade 1, and (b) administering the original full target dose for at least one week, two weeks, three weeks, four weeks or a month, two months, or three months, or one year, or two years, or three years, or four years, or five years, or seven years, or ten years.
  • the total daily dose is administered three times per day, with food.
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality as follows: (a) administering 800 mg/day or 801 mg/day pirfenidone for one week, or until the liver function biomarkers return to Grade 0 or Grade 1, (b) administering 1600 mg/day or 1602 mg/day pirfenidone for one week, and (c) administering the original full target dose for a time period of at least one week, two weeks, three weeks, four weeks or a month, two months, or three months, or one year, or two years, or three years, or four years, or five years, or seven years, or ten years.
  • the total daily dose is administered three times per day, with food.
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality as follows: (a) discontinuing pirfenidone for one week, or until the liver function biomarkers return to Grade 0 or Grade 1, (b) administering 800 mg/day or 801 mg/day pirfenidone for one week, (c) administering 1600 mg/day or 1602 mg/day pirfenidone for one week, and (d) administering the original full target dose for a time period of at least one week, two weeks, three weeks, four weeks or a month, two months, or three months, or one year, or two years, or three years, or four years, or five years, or seven years, or ten years.
  • the total daily dose is administered three times per day, with food.
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality at a permanently reduced dose, e.g. 800 or 801 mg/day, or 1600 or 1602 mg/day.
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality as follows: administering 1600 mg/day or 1602 mg/day pirfenidone for a time period of at least one week, two weeks, three weeks, four weeks or a month, two months, or three months, or one year, or two years, or three years, or four years, or five years, or seven years, or ten years.
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality as follows: (a) administering 800 mg/day or 801 mg/day pirfenidone for a week, or until biomarkers of liver function are within normal limits, and (b) administering 1600 mg/day or 1602 mg/day pirfenidone to the patient for a time period of at least one week, two weeks, three weeks, four weeks or a month, two months, or three months, or one year, or two years, or three years, or four years, or five years, or seven years, or ten years.
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality as follows: (a) discontinuing pirfenidone for about one week, or until the liver function biomarkers return to Grade 0 or Grade 1, (b) administering 800 mg/day or 801 mg/day pirfenidone for a week, or until biomarkers of liver function are within normal limits, and (c) administering 1600 mg/day or 1602 mg/day pirfenidone to the patient for a time period of at least one week, two weeks, three weeks, four weeks or a month, two months, or three months, or one year, or two years, or three years, or four years, or five years, or seven years, or ten years.
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality as follows: (a) discontinuing pirfenidone for one week, or until the liver function biomarkers return to Grade 0 or Grade 1, and (b) administering 1600 mg/day or 1602 mg/day pirfenidone to the patient for a time period of at least one week, two weeks, three weeks, four weeks or a month, two months, or three months, or one year, or two years, or three years, or four years, or five years, or seven years, or ten years.
  • any of the reduced doses of pirfenidone may be administered for a time period of 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, or until the level of at least one biomarker of liver function has returned to within normal limits, or until all biomarkers or liver function has returned to within normal limits.
  • the biomarker of liver function is alanine transaminase, and/or aspartate transaminase, and optionally bilirubin, and/or alkaline phosphatase. Elevated gamma-glutamyl transferase has been observed in some patients receiving pirfenidone, without clinical liver impairment, and thus elevated gamma-glutamyl transferase alone is not necessarily a sign of liver impairment. In any of the embodiments described herein, biomarkers of liver function can exclude gamma-glutamyl transferase.
  • the abnormal level of alanine transaminase or aspartate transaminase and optionally alkaline phosphatase is greater than 2.5- fold increased compared to the upper limit of normal (ULN).
  • the abnormal level of alanine transaminase or aspartate transaminase, and optionally alkaline phosphatase is greater than 2.5- to 5-fold increased compared to the upper limit of normal (ULN), i.e. a "liver function Grade 2 abnormality".
  • the abnormal level of bilirubin may be greater than 1.5- to 3-fold increased compared to the upper limit of normal (ULN), i.e., a "liver function Grade 2 abnormality".
  • the abnormal biomarkers of liver function e.g. elevated alanine transaminase and/or aspartate transaminase and optionally elevated bilirubin, are accompanied by clinical signs of impaired liver function such as jaundice.
  • the invention provides pirfenidone for administering a full therapeutically effective dose of pirfenidone to a patient that has exhibited abnormal levels of biomarkers of liver function after the patient has been treated with pirfenidone as set out in the claims.
  • liver function abnormalities can be indicative of drug-induced liver injury (hepatotoxicity)
  • even patients that exhibit abnormal liver function may continue taking pirfenidone at the original full target dose, optionally after a short time period of discontinuing pirfenidone or taking the pirfenidone at reduced doses.
  • This administration regimen has the advantage of maximizing the time on the full target dose of drug and therefore the potential for a beneficial therapeutic effect.
  • the invention optionally includes identifying abnormal liver function in a patient receiving pirfenidone, and monitoring biomarkers of liver function in a patient receiving a reduced dose of pirfenidone.
  • AST and/or ALT are elevated, e.g. to a Grade 2 level.
  • AST and bilirubin may be elevated, or AST or ALP may be elevated, or AST and GGT may be elevated, or ALT and bilirubin may be elevated, or ALT and ALP may be elevated, or ALT and GGT may be elevated, e.g., to a Grade 2 level.
  • biomarkers of liver function may be elevated, e.g., ALT and AST and bilirubin, or ALT and AST and ALP, to a Grade 2.
  • biomarkers of liver function can exclude gamma-glutamyl transferase.
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality after pirfenidone administration as follows: (a) administering at least 1600 mg/day or 1602 mg/day pirfenidone, or 23 mg/kg/day (e.g. 22-24 mg/kg/day) as far as encompassed by the claims, or from 1400-1800 mg/day pirfenidone, or from 20 mg/kg/day to 26 mg/kg/day as far as encompassed by the claims, for a time period. In some embodiments, step (a) is followed by (b) administering the original full target dose.
  • the original full target dose is continued without a temporary reduction or discontinuation of the dose.
  • the time period of step (a) is 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks, four weeks, 1 month, or until the level of at least one biomarker of liver function has returned to within normal limits, or until all biomarkers or liver function has returned to within normal limits.
  • step (b) is carried out for a time period of at least one week, two weeks, three weeks, four weeks or a month, two months, or three months, or one year, or two years, or three years, or four years, or five years, or seven years, or ten years, or more.
  • the invention includes measuring one or more biomarkers of liver function during step (a) and/or step (b).
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality as follows: (a) administering at least 800 mg/day or 801 mg/day pirfenidone, or 11 mg/kg/day (e.g. 10-12 mg/kg/day) as far as encompassed by the claims, or from 600-1000 mg/day, or from 700-900 mg/day, or from 8 mg/kg/day to 15 mg/kg/day as far as encompassed by the claims, for a time period, (b) administering at least 1600 mg/day or 1602 mg/day pirfenidone, or 23 mg/kg/day (e.g.
  • the time period of step (a) is 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks, four weeks, 1 month, or until the level of at least one biomarker of liver function has returned to within normal limits, or to Grade 1, or until all biomarkers or liver function has returned to within normal limits, or to Grade 1.
  • step (b) is 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks, four weeks, 1 month, or until the level of at least one biomarker of liver function has returned to within normal limits, or to Grade 1, or until all biomarkers or liver function has returned to within normal limits, or to Grade 1.
  • step (c) is carried out for a time period of at least one week, two weeks, three weeks, four weeks or a month, two months, or three months, or one year, or two years, or three years, or four years, or five years, or seven years, or ten years, or more.
  • the invention includes measuring one or more biomarkers of liver function during step (a) and/or step (b) and/or step (c).
  • pirfenidone is administered to a patient exhibiting a liver function Grade 2 abnormality as follows: (a) discontinuing pirfenidone for a time period, (b) administering at least 800 mg/day or 801 mg/day pirfenidone, or 11 mg/kg/day (e.g.
  • the time period of step (a) is 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks, four weeks, 1 month, or until the level of at least one biomarker of liver function has returned to within normal limits, or to Grade 1, or until all biomarkers or liver function has returned to within normal limits, or to Grade 1.
  • the time period of step (b) is 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks, four weeks, 1 month, or until the level of at least one biomarker of liver function has returned to within normal limits, or to Grade 1, or until all biomarkers or liver function has returned to within normal limits, or to Grade 1.
  • step (c) is 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks, four weeks, 1 month, or until the level of at least one biomarker of liver function has returned to within normal limits, or to Grade 1, or until all biomarkers or liver function has returned to within normal limits, or to Grade 1.
  • step (d) is carried out for a time period of at least one week, two weeks, three weeks, four weeks or a month, two months, or three months, or one year, or two years, or three years, or four years, or five years, or seven years, or ten years, or more.
  • the invention includes measuring one or more biomarkers of liver function during step (a) and/or step (b) and/or step (c) and/or step (d).
  • Pirfenidone can be provided in tablet or capsule forms or any other oral dosage form, and typically is formulated for oral administration. Exemplary capsule formulations are described in WO 2007/038315 (Int'1 Appl. No. PCT/US2006/037057 ).
  • Pirfenidone therapy can be associated with adverse effects including photosensitivity rash, anorexia (decreased appetite), stomach discomfort, nausea, heartburn, drowsiness (somnolence), fatigue, upper respiratory tract infection, fever, positive urinary occult blood, elevation of C-reactive protein (CRP), decreased weight, headache, constipation, and malaise.
  • Abnormal liver function also can occur as an adverse effect (AE) in patients receiving pirfenidone.
  • AE adverse effect
  • the baseline liver function of the patient Prior to receiving pirfenidone, can be, and typically is, normal. Liver function can be assessed by various means known in the art, such as blood chemistry tests measuring biomarkers of liver function.
  • biomarkers of liver function include, but are not limited to, alanine transaminase (ALT), aspartate transaminase (AST), bilirubin, alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT).
  • ALT alanine transaminase
  • AST aspartate transaminase
  • ALP alkaline phosphatase
  • GTT gamma-glutamyl transferase
  • ALT Alanine transaminase
  • SGPT serum glutamic pyruvate transaminase
  • ALAT alanine aminotransferase
  • AST Aspartate transaminase
  • SGOT serum glutamic oxaloacetic transaminase
  • ASAT aspartate aminotransferase
  • AST can increase in response to liver damage. Elevated AST also can result from damage to other sources, including red blood cells, cardiac muscle, skeletal muscle, kidney tissue, and brain tissue. The ratio of AST to ALT can be used as a biomarker of liver damage.
  • Bilirubin is a catabolite of heme that is cleared from the body by the liver. Conjugation of bilirubin to glucuronic acid by hepatocytes produces direct bilirubin, a watersoluble product that is readily cleared from the body. Indirect bilirubin is unconjugated, and the sum of direct and indirect bilirubin constitutes total bilirubin. Elevated total bilirubin can be indicative of liver impairment.
  • Alkaline phosphatase hydrolyzes phosphate groups from various molecules and is present in the cells lining the biliary ducts of the liver.
  • ALP levels in plasma can rise in response to liver damage, and are higher in growing children and elderly patients with Paget's disease.
  • elevated ALP levels usually reflect biliary tree disease.
  • Adverse effect Grades for abnormal liver function are defined herein by the modified Common Toxicity Criteria (CTC) provided in Table 1. See the Common Terminology Criteria for Adverse Events v3.0 (CTCAE) published August 9, 2006 by the National Cancer Institute . Table 1. Modified Common Toxicity Criteria Grade Toxicity 0 1 2 3 4 ALT WNL >ULN-2.5 x ULN >2.5-5 x ULN >5-20 x ULN >20 x ULN AST WNL >ULN-2.5 x ULN >2.5-5 x ULN >5-20 x ULN >20 x ULN Bilirubin WNL >ULN-1.5 x ULN >1.5-3 x ULN >3-10 x ULN >10 x ULN ALP WNL >ULN-2.5 x ULN >2.5-5 x ULN >5-20 x ULN >20 x ULN GGT WNL >ULN-2.5 x ULN >2.5-5 x ULN >
  • the ULN for various indicators of liver function depends on the assay used, the patient population, and each laboratory's normal range of values for the specified biomarker, but can readily be determined by the skilled practitioner. Exemplary values for normal ranges for a healthy adult population are set forth in Table 2 below. See Cecil Textbook of Medicine, pp. 2317-2341, W.B. Saunders & Co. (1985 ). Table 2 ALT 8-20 U/L AST 8-20 U/L Bilirubin 0.2-1.0 mg/dL 3.4-17.1 ⁇ mol/L ALP 20-70 U/L GGT Men: 9-50 U/L Women: 8-40 U/L
  • Grade 0 levels are characterized by biomarker levels within normal limits (WNL).
  • Normal refers to Grade 0 adverse effects.
  • Abnormal liver function, as used herein, refers to Grade 1 and above adverse effects.
  • Grade 1 liver function abnormalities include elevations in ALT, AST, ALP, or GGT greater than the ULN and less than or equal to 2.5-times the ULN.
  • Grade 1 liver function abnormalities also include elevations of bilirubin levels greater than the ULN and less than or equal to 1.5-times the ULN.
  • Grade 2 liver function abnormalities include elevations in alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), or gamma-glutamyl transferase (GGT) greater than 2.5-times and less than or equal to 5-times the upper limit of normal (ULN).
  • Grade 2 liver function abnormalities also include elevations of bilirubin levels greater than 1.5-times and less than or equal to 3-times the ULN.
  • Grade 3 liver function abnormalities include elevations in ALT, AST, ALP, or GGT greater than 5-times and less than or equal to 20-times the ULN.
  • Grade 3 liver function abnormalities also include elevations of bilirubin levels greater than 3-times and less than or equal to 10-times the ULN.
  • Grade 4 liver function abnormalities include elevations in ALT, AST, ALP, or GGT greater than 20-times the ULN. Grade 4 liver function abnormalities also include elevations of bilirubin levels greater than 10 the ULN.
  • the present disclosure provides pirfenidone for treating a patient having idiopathic pulmonary fibrosis and receiving a full target dose of pirfenidone, wherein the full target dose is 2400 or 2403 mg pirfenidone per day.
  • a patient with abnormal liver function as set out in the claims is administered a second dose of pirfenidone, wherein the second dose is 1600 or 1602 mg pirfenidone per day until liver function is within normal limits, followed by administering the patient the full target dose of 2400 or 2403 mg pirfenidone per day.
  • the invention provides pirfenidone as a medicament wherein the administration pattern of the medicament comprises administering according to any of the ways described herein.
  • the invention provides pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis according to any of the treatment regimes as described above with respect to the invention for administering pirfenidone to a patient for treating idiopathic pulmonary fibrosis.
  • Pirfenidone is packaged and presented for use in a treating a patient with idiopathic pulmonary fibrosis according to such treatment regimes.
  • Pirfenidone is administered to the patient in accordance with the treatment regimes as described above.
  • the patient is one who has exhibited abnormal biomarkers of liver function after pirfenidone administration as is described above with respect to the invention for administering pirfenidone to a patient for treating idiopathic pulmonary fibrosis.
  • the invention includes pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis, said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration as set out in the claims, wherein said patient is administered pirfenidone at doses of 2400 mg/day or 2403 mg/day.
  • said patient is administered pirfenidone at doses lower than 2400 mg/day for a time period.
  • the invention further includes pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis, said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration as set out in the claims, wherein said patient is administered pirfenidone at doses of 1600 mg/day or 1602 mg/day.
  • said patient is administered pirfenidone at doses lower than 1600 mg/day or 1602 mg/day for a time period.
  • the invention provides the use of pirfenidone in the manufacture of a medicament for treating a patient with idiopathic pulmonary fibrosis according to any of the treatment regimes as described above with respect to any of the invention.
  • the medicaments manufactured according to this aspect of the invention are for use in treating a patient with idiopathic pulmonary fibrosis in accordance with such treatment regimes.
  • the medicament so manufactured is administered to the patient in accordance with the treatment regimes as described above.
  • the patient is one who has exhibited abnormal biomarkers of liver function after pirfenidone administration as is described above with respect to the pirfenidone of the invention for administering pirfenidone to a patient for treating idiopathic pulmonary fibrosis.
  • the invention includes the use of pirfenidone in the manufacture of a medicament for treating a patient with idiopathic pulmonary fibrosis, said patient having exhibited a Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein said patient is administered pirfenidone at doses of 2400 mg/day or 2403 mg/day.
  • said patient is administered pirfenidone at doses lower than 2400 mg/day for a time period.
  • the preferences expressed with respect to the preferred embodiments of the aspect of the invention relating to pirfenidone for administering pirfenidone to treat a patient with idiopathic pulmonary fibrosis apply in the same way.
  • the examples relate to pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis, and to use of pirfenidone in the manufacture of a medicament for treating a patient with idiopathic pulmonary fibrosis.
  • Patients begin pirfenidone treatment by receiving escalating doses of pirfenidone over a period of 15 days until the full maintenance dose is reached. Specifically, from days 1 to 7, patients are administered one capsule of 267 mg pirfenidone three times per day. During days 8 to 14, patients receive two capsules of 267 mg pirfenidone three times per day. From day 15 onward, patients are treated with three capsules of 267 mg pirfenidone three times per day. Pirfenidone is administered orally, and each dose should be taken with food. If the patient is unable to eat, then the pirfenidone dose should be taken with milk or juice (excluding grapefruit juice).
  • Pirfenidone is known to cause photosensitivity reactions; therefore, throughout the treatment period, patients should use sun block that protects against at least UV-A with a sun protective factor (SPF) of 50. In addition, patients should wear appropriate clothing to minimize sun exposure, and if possible, avoid other medications known to cause photosensitivity reactions.
  • SPF sun protective factor
  • pirfenidone is administered orally to patients three times per day to provide a daily dose of 2403 mg pirfenidone.
  • Each of the three doses of 801 mg pirfenidone includes three capsules of 267 mg pirfenidone each.
  • the contents of the pirfenidone 267 mg capsules are pirfenidone (82.15%); croscarmellose sodium (8.15%); microcrystalline cellulose (7.39%); povidine, USP, EP (1.85%); and magnesium stearate (0.46%).
  • Patients are treated with pirfenidone for up to 72 weeks. Some patients are treated longer than 72 weeks. At weeks 2, 4, 6, 12, and every 12 weeks ( ⁇ 2 weeks) thereafter during the treatment period, with the exception of week 72 and the treatment completion visit, patients are examined and histories are collected as detailed in the steps below.
  • Patient history is collected to include review of adverse effects (AEs) and severe adverse effects (SAEs), use of concomitant medications, use of oxygen, hospitalizations, IPF exacerbations or acute respiratory decompensation, and dosing.
  • AEs adverse effects
  • SAEs severe adverse effects
  • Pulmonary function is assessed by spirometry before and after administration of bronchodilators. Forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV 1) are measured.
  • FVC Forced vital capacity
  • FEV 1 forced expiratory volume in 1 second
  • Clinical laboratory tests are performed, including hematology, serum chemistries, pregnancy tests for women of childbearing capacity, and urinalysis with microscopic examination.
  • UCSD SOBQ University of California at San Diego Shortness of Breath Questionnaire
  • SGRQ St. George's Hospital Respiratory Questionnaire
  • WHO QOL World Health Organization Quality of Life
  • ECG electrocardiogram
  • PFT pulmonary function test
  • PK pharmacokinetic
  • ALT alanine transaminase
  • AST aspartate transaminase
  • bilirubin not within the invention at baseline or after the start of pirfenidone dosing up to and including week 6, an additional safety chemistry blood test must be obtained between weeks 8 and 10.
  • pirfenidone Patients are treated with pirfenidone in accordance with Example 1. During the course of pirfenidone treatment, patients exhibiting abnormal liver function test results are candidates for dose modification. As described in Example 1, serum chemistry tests are performed at scheduled intervals during the treatment period to monitor various parameters, including biomarkers of liver function such as alanine transaminase (ALT), aspartate transaminase (AST), bilirubin, alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT).
  • ALT alanine transaminase
  • AST aspartate transaminase
  • bilirubin bilirubin
  • ALP alkaline phosphatase
  • GTT gamma-glutamyl transferase
  • the pirfenidone dose is reduced to one capsule of 267 mg pirfenidone three times per day. While receiving the reduced pirfenidone dose, the patient undergoes additional monitoring of AST, ALT and bilirubin. The reduced pirfenidone dose is continued at least until AST, ALT and bilirubin are all Grade 1 or within normal limits (Grade 0). The reduced pirfenidone dose can be administered for a period of time after AST, ALT and bilirubin have reached Grade 1 or Grade 0.
  • the pirfenidone dose can be re-escalated in a manner consistent with the initial dose escalation, up to a dose of 6 capsules per day.
  • the pirfenidone dose also can be re-escalated in a manner consistent with the initial dose escalation, up to the maximum of 9 capsules per day.
  • Serum chemistry tests are optionally performed at scheduled intervals during the escalation period, e.g. weekly or every 2 weeks, or every 3 weeks, or every month to monitor various parameters, including biomarkers of liver function such as alanine transaminase (ALT), aspartate transaminase (AST), bilirubin, alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT).
  • ALT alanine transaminase
  • AST aspartate transaminase
  • bilirubin bilirubin
  • ALP alkaline phosphatase
  • GTT gamma-glutamyl transferase
  • pirfenidone Patients are treated with pirfenidone in accordance with Example 1. During the course of pirfenidone treatment, patients exhibiting abnormal liver function test results are candidates for dose modification. As described in Example 1, serum chemistry tests are performed at scheduled intervals during the treatment period to monitor various parameters, including biomarkers of liver function such as alanine transaminase (ALT), aspartate transaminase (AST), bilirubin, alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT).
  • ALT alanine transaminase
  • AST aspartate transaminase
  • bilirubin bilirubin
  • ALP alkaline phosphatase
  • GTT gamma-glutamyl transferase
  • the pirfenidone dose is discontinued. Following discontinuation of the pirfenidone dose, the patient undergoes additional monitoring of AST, ALT and bilirubin. Pirfenidone dosing is discontinued at least until AST, ALT and bilirubin are all Grade 1 or within normal limits (Grade 0). The pirfenidone dose can be discontinued for a period of time after AST, ALT and bilirubin have reached Grade 1 or Grade 0.
  • the pirfenidone dose is re-escalated in a manner consistent with the initial dose escalation, up to a dose of 6 or 9 capsules per day, i.e. 1602 mg/day or 2403 mg/day.
  • the pirfenidone dose is re-instituted at a dose of 6 capsules per day, i.e. 1602 mg/day, and re-escalated after 1 week to the maximum of 9 capsules per day.
  • Serum chemistry tests are optionally performed at scheduled intervals during the escalation period, e.g. weekly, or every 2 weeks, or every month, to monitor various parameters, including biomarkers of liver function such as alanine transaminase (ALT), aspartate transaminase (AST), bilirubin, alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT).
  • ALT alanine transaminase
  • AST aspartate transaminase
  • bilirubin bilirubin
  • ALP alkaline phosphatase
  • GTT gamma-glutamyl transferase
  • pirfenidone Patients are treated with pirfenidone in accordance with Example 1. During the course of pirfenidone treatment, patients exhibiting abnormal liver function test results are candidates for dose modification. As described in Example 1, serum chemistry tests are performed at scheduled intervals during the treatment period to monitor various parameters, including biomarkers of liver function such as alanine transaminase (ALT), aspartate transaminase (AST), bilirubin, alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT).
  • ALT alanine transaminase
  • AST aspartate transaminase
  • bilirubin bilirubin
  • ALP alkaline phosphatase
  • GTT gamma-glutamyl transferase
  • the pirfenidone dose is reduced to two capsules of 267 mg pirfenidone three times per day, i.e. 1602 mg/day. While receiving the reduced pirfenidone dose, the patient undergoes additional monitoring of AST, ALT and bilirubin. The reduced pirfenidone dose is continued at least until AST, ALT and bilirubin are all Grade 1 or within normal limits (Grade 0). The reduced pirfenidone dose can be administered for a period of time after AST, ALT and bilirubin have reached Grade 1 or Grade 0.
  • the pirfenidone dose can be re-escalated to the maximum of 9 capsules per day, i.e. 2403 mg.
  • ALT alanine transaminase
  • AST aspartate transaminase
  • ALP alkaline phosphate
  • GTT gamma-glutamyl transferase
  • a patient exhibited a Grade 2 increase in any one of AST or ALT, the pirfenidone dose was not reduced for some patients.
  • the patient continued to receive the full target dose of 2403 mg/day. While receiving the full target dose, the patient was monitored for AST, ALT, and bilirubin levels.
  • study drug dose was reduced to 1602 mg/day and then increased to 2403 mg/day for remainder of study participation, and ALT returned to Grade 0.
  • the third patient had study drug dose reduced to 801 mg/day, ultimately completing study at 1602 mg/day, at which time ALT returned to Grade 0.
  • the dose for this patient was initially decreased to 1602 mg/day, then discontinued, and then resumed at 1602 mg/day.
  • treatment was permanently discontinued because a Grade 2 elevation of AST coincided with a Grade 3 ALT elevation in liver function tests.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
EP09252572A 2008-11-10 2009-11-06 Modifying pirfenidone treatment for patients with atypical liver function Active EP2191831B1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP12166073A EP2505199A1 (en) 2008-11-10 2009-11-06 Modifying pirfenidone treatment for patients with atypical liver function
EP11001414.9A EP2343070B1 (en) 2008-11-10 2009-11-06 Pirfenidone treatment for patients with atypical liver function
DK11001414.9T DK2343070T3 (en) 2008-11-10 2009-11-06 Pirfenidone therapy for patients with atypical liver function
EP12166074.0A EP2500019B1 (en) 2008-11-10 2009-11-06 Modifying pirfenidone treatment for patients with fibrosis
SI200930033T SI2191831T1 (sl) 2008-11-10 2009-11-06 Modificiranje zdravljenja s pirfenidonom za bolnike z atipiäśno jetrno funkcijo
MEP-2011-113A ME01189B (me) 2008-11-10 2009-11-06 Modifikovanje lečenja pirfenidonom za pacijente sa atipičnom funkcijom jetre
PL11001414T PL2343070T3 (pl) 2008-11-10 2009-11-06 Leczenie pirfenidonem dla pacjentów z atypową funkcją wątroby
PL09252572T PL2191831T3 (pl) 2008-11-10 2009-11-06 Modyfikowanie leczenia pirfenidonem dla pacjentów z atypową funkcją wątroby
CY20111100614T CY1111595T1 (el) 2008-11-10 2011-06-28 Τροποποιηση της θεραπειας με πιρφενιδονη για ασθενεις με μη φυσιολογικη ηπατικη λειτουργια

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11310708P 2008-11-10 2008-11-10
US12/428,393 US7566729B1 (en) 2008-11-10 2009-04-22 Modifying pirfenidone treatment for patients with atypical liver function
US22894309P 2009-07-27 2009-07-27
US12/553,292 US7635707B1 (en) 2008-11-10 2009-09-03 Pirfenidone treatment for patients with atypical liver function

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP11001414.9A Division EP2343070B1 (en) 2008-11-10 2009-11-06 Pirfenidone treatment for patients with atypical liver function
EP12166073A Division EP2505199A1 (en) 2008-11-10 2009-11-06 Modifying pirfenidone treatment for patients with atypical liver function
EP12166074.0A Division EP2500019B1 (en) 2008-11-10 2009-11-06 Modifying pirfenidone treatment for patients with fibrosis

Publications (2)

Publication Number Publication Date
EP2191831A1 EP2191831A1 (en) 2010-06-02
EP2191831B1 true EP2191831B1 (en) 2011-03-30

Family

ID=41427890

Family Applications (4)

Application Number Title Priority Date Filing Date
EP09252572A Active EP2191831B1 (en) 2008-11-10 2009-11-06 Modifying pirfenidone treatment for patients with atypical liver function
EP12166073A Withdrawn EP2505199A1 (en) 2008-11-10 2009-11-06 Modifying pirfenidone treatment for patients with atypical liver function
EP12166074.0A Revoked EP2500019B1 (en) 2008-11-10 2009-11-06 Modifying pirfenidone treatment for patients with fibrosis
EP11001414.9A Revoked EP2343070B1 (en) 2008-11-10 2009-11-06 Pirfenidone treatment for patients with atypical liver function

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP12166073A Withdrawn EP2505199A1 (en) 2008-11-10 2009-11-06 Modifying pirfenidone treatment for patients with atypical liver function
EP12166074.0A Revoked EP2500019B1 (en) 2008-11-10 2009-11-06 Modifying pirfenidone treatment for patients with fibrosis
EP11001414.9A Revoked EP2343070B1 (en) 2008-11-10 2009-11-06 Pirfenidone treatment for patients with atypical liver function

Country Status (39)

Country Link
US (9) US7635707B1 (ko)
EP (4) EP2191831B1 (ko)
JP (3) JP2012508253A (ko)
KR (1) KR101699501B1 (ko)
CN (1) CN102209543A (ko)
AP (1) AP2011005740A0 (ko)
AT (1) ATE503480T1 (ko)
AU (3) AU2009313302B2 (ko)
BR (1) BRPI0921022A2 (ko)
CA (2) CA2709997C (ko)
CL (1) CL2011000966A1 (ko)
CO (1) CO6382132A2 (ko)
CU (1) CU20110100A7 (ko)
CY (2) CY1111595T1 (ko)
DE (1) DE602009000986D1 (ko)
DK (2) DK2191831T3 (ko)
EA (1) EA022482B1 (ko)
EC (1) ECSP11011039A (ko)
ES (3) ES2387421T3 (ko)
GE (1) GEP201706719B (ko)
HK (3) HK1145138A1 (ko)
HR (2) HRP20110478T1 (ko)
IL (1) IL212064A (ko)
MA (1) MA32880B1 (ko)
ME (1) ME01189B (ko)
MX (1) MX2011004904A (ko)
MY (1) MY159353A (ko)
NI (1) NI201100091A (ko)
PE (1) PE20110683A1 (ko)
PL (2) PL2191831T3 (ko)
PT (2) PT2191831E (ko)
RS (2) RS53721B1 (ko)
SI (2) SI2343070T1 (ko)
SM (2) SMT201100030B (ko)
SV (1) SV2011003897A (ko)
TN (1) TN2011000217A1 (ko)
TW (2) TWI419877B (ko)
WO (1) WO2010054294A1 (ko)
ZA (1) ZA201102411B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034994A1 (en) * 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
KR20110114684A (ko) * 2009-01-26 2011-10-19 인터뮨, 인크. 급성 심근 경색 및 연관된 질환을 치료하는 방법
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US10092552B2 (en) 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
EP2672539B1 (en) * 2011-10-13 2016-09-28 Mitsui Chemicals, Inc. Polymeric piezoelectric material and process for producing the same
BR112014017626A2 (pt) * 2012-01-18 2018-05-22 Genentech Inc métodos para tratar uma doença ou disfunção, métodos de identificação de um indivíduo, método para prever se um indivíduo com uma doença ou disfunção tem mais ou menos probabilidade para desenvolver toxicidade ao tratamento, método para determinar se um indivíduo com uma doença ou disfunção deve continuar ou suspender o tratamento que compreende um modulador de fgf19, método de otimização de eficácia terapêutica e método de ensaio
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014151517A1 (en) * 2013-03-15 2014-09-25 Intermune, Inc. Methods of improving microvascular integrity
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP2017503839A (ja) * 2014-01-24 2017-02-02 オースペックス ファーマシューティカルズ インコーポレイテッド 置換ｎ−アリールピリジノン
MX2016012248A (es) * 2014-03-25 2017-04-27 Leading Biosciences Inc Composiciones para el tratamiento de autodigestion.
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CN107427007B (zh) * 2015-02-05 2022-02-11 纪念斯隆凯特林癌症中心 用于治疗水肿的组合物和方法
MA41544A (fr) * 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
CN108289883A (zh) * 2015-12-11 2018-07-17 豪夫迈·罗氏有限公司 维莫德吉与吡非尼酮联合疗法
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2018026441A1 (en) * 2016-08-01 2018-02-08 The Regents Of The University Of California Methods for preventing or treating fibrotic diseases
MX364040B (es) * 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
AU2018317352B2 (en) * 2017-08-12 2020-11-19 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in reproductive and digestive tract fibrosis
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
JP2021534153A (ja) * 2018-08-15 2021-12-09 アイビバ バイオファーマ インコーポレイテッド Ｖｅｇｆおよびｔｇｆベータのマルチキナーゼ阻害剤およびその使用
WO2021057599A1 (zh) * 2019-09-26 2021-04-01 深圳先进技术研究院 吡非尼酮在制备防治类风湿性关节炎的药物中的应用
TW202133844A (zh) 2019-12-04 2021-09-16 瑞士商愛杜西亞製藥有限公司 吖丁啶lpa1受體拮抗劑與抗纖維化藥劑之組合
AU2022443590A1 (en) 2022-02-28 2024-10-17 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000828A (en) 1907-07-25 1911-08-15 Pierre Lorillard Conveyer.
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
CA1244894A (en) 1985-09-27 1988-11-15 William A. Cole Low voltage class b amplifier with low value decoupling capacitors
JPH02215719A (ja) 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6956044B1 (en) * 2000-02-21 2005-10-18 Margolin Solomon B Compositions and methods for treatment of epilepsy
SE0101762D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab New use
BR0309095A (pt) 2002-04-10 2005-02-09 Applied Research Systems Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
US20060110358A1 (en) 2002-08-28 2006-05-25 Hsu Henry H Combination therapy for treatment of fibrotic disorders
JP4542743B2 (ja) 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
EP1599171A2 (en) 2003-02-28 2005-11-30 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
US7250905B2 (en) 2003-04-09 2007-07-31 Mano Dorsey Judd Virtual antenna technology (VAT) and applications
CA2525184C (en) 2003-05-09 2012-10-30 Centocor, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
WO2004103296A2 (en) 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US20070053877A1 (en) 2003-08-21 2007-03-08 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
CN1266144C (zh) 2003-09-01 2006-07-26 上海凯曼生物科技有限公司 黄芩甙和黄芩甙元的用途和剂型
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
EP1684703A4 (en) 2003-11-05 2008-10-01 Centocor Inc METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH MCP-1
CA2545813C (en) 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
DE10394357T5 (de) * 2003-12-30 2007-03-08 Council Of Scientific & Industrial Research Oro-dentale-Kräuterpflegezusammensetzung und Verfahren zur Herstellung derselben
WO2005091853A2 (en) 2004-02-27 2005-10-06 Centocor, Inc. Methods and compositions for treating il-13 related pathologies
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
WO2005110478A2 (en) 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
US20060037057A1 (en) 2004-05-24 2006-02-16 Sharp Laboratories Of America, Inc. Method and system of enabling trick play modes using HTTP GET
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US20060246070A1 (en) 2004-09-30 2006-11-02 Heavner George A Methods and compositions for treating renal cell carcinoma related pathologies
JP2008515893A (ja) 2004-10-05 2008-05-15 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 肺線維症を処置するためのｔａｆｉ阻害剤およびそれらの使用
CA2585703A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease
WO2006050058A2 (en) 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
US20090110633A1 (en) 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
WO2006105538A2 (en) 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
CN1846699A (zh) 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
US20060258706A1 (en) 2005-04-29 2006-11-16 Manohar Saindane Solid forms of a JNK inhibitor
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
WO2006125077A2 (en) 2005-05-18 2006-11-23 Intermune, Inc. Non-natural chemokine receptor ligands and methods of use thereof
JP2008540678A (ja) 2005-05-18 2008-11-20 バイオジェン アイデック インク． 線維形成状態の治療方法
CN102816170A (zh) 2005-07-25 2012-12-12 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
WO2007038264A2 (en) 2005-09-22 2007-04-05 Biogen Idec Ma Inc. Gapr-1 methods
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
ATE551057T1 (de) 2005-10-31 2012-04-15 Intermune Inc Zusammensetzungen von pirfenidon/toll-like rezeptor (tlr)-antagonisten und verfahren zu ihrer verwendung zur stimulierung der produktion des granulozyten-kolonie-stimulierenden faktors (g-csf)
US20110034495A1 (en) 2005-11-23 2011-02-10 Intermune, Inc. Method of Modulating Stress-Activated Protein Kinase System
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
BRPI0709950A2 (pt) 2006-04-13 2011-08-02 Actelion Pharmaceuticals Ltd uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin
US20080003635A1 (en) 2006-06-12 2008-01-03 Intermune, Inc. High Throughput Collagen Synthesis Assay
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
CA2708004C (en) 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
DK2124945T3 (da) * 2006-12-18 2011-08-01 Intermune Inc Fremgangsmåde til at give pirfenidonterapi til en patient
KR20100016045A (ko) 2007-03-30 2010-02-12 센토코 오르토 바이오테크 인코포레이티드 염증성 질환의 치료를 위한 ｃｘｃｌ１３ 길항제 및 이의 용도
AU2007201663A1 (en) 2007-04-16 2008-10-30 Nautilus Biotech Oral dosage formulations of protease resistant polypeptides
CA2583716A1 (en) 2007-04-18 2008-10-18 Nautilus Biotech Oral dosage formulations of protease resistant polypeptides
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20080287508A1 (en) 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) * 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Pirespa Tablets", October 2008, SHIONOGI & CO., JP *

Also Published As

Publication number Publication date
ES2387421T3 (es) 2012-09-21
US20190060299A1 (en) 2019-02-28
CO6382132A2 (es) 2012-02-15
EA022482B1 (ru) 2016-01-29
JP2015007132A (ja) 2015-01-15
PE20110683A1 (es) 2011-10-20
JP2012508253A (ja) 2012-04-05
ME01189B (me) 2011-12-31
TW201341361A (zh) 2013-10-16
RS51787B (en) 2011-12-31
AU2011200385A1 (en) 2011-02-17
US20170100381A1 (en) 2017-04-13
CY1111595T1 (el) 2015-10-07
MY159353A (en) 2016-12-30
US8592462B2 (en) 2013-11-26
TWI419877B (zh) 2013-12-21
HK1153668A1 (en) 2012-04-05
US20160250198A1 (en) 2016-09-01
PL2191831T3 (pl) 2011-09-30
EA201170669A1 (ru) 2011-10-31
WO2010054294A1 (en) 2010-05-14
AU2011200385B2 (en) 2013-04-18
BRPI0921022A2 (pt) 2015-12-29
RS53721B1 (en) 2015-04-30
TW201020232A (en) 2010-06-01
US7635707B1 (en) 2009-12-22
SI2343070T1 (sl) 2015-01-30
US20180200242A1 (en) 2018-07-19
ATE503480T1 (de) 2011-04-15
CN102209543A (zh) 2011-10-05
SMT201500088B (it) 2015-05-05
AU2010212371B2 (en) 2010-12-23
SMT201100030B (it) 2011-09-09
DE602009000986D1 (de) 2011-05-12
AU2009313302A1 (en) 2010-05-14
KR101699501B1 (ko) 2017-01-24
MA32880B1 (fr) 2011-12-01
DK2343070T3 (en) 2015-01-05
ES2525543T3 (es) 2014-12-26
US20140073673A1 (en) 2014-03-13
CA2765402A1 (en) 2010-05-14
EP2343070B1 (en) 2014-10-15
CL2011000966A1 (es) 2011-08-19
CA2709997C (en) 2012-03-27
CU20110100A7 (es) 2012-01-31
TN2011000217A1 (en) 2012-12-17
EP2505199A1 (en) 2012-10-03
US20110263656A1 (en) 2011-10-27
ECSP11011039A (es) 2011-07-29
EP2191831A1 (en) 2010-06-02
AU2010212371A1 (en) 2010-09-09
AP2011005740A0 (en) 2011-06-30
IL212064A0 (en) 2011-06-30
HRP20110478T1 (hr) 2011-07-31
CA2709997A1 (en) 2010-05-14
ES2578715T3 (es) 2016-07-29
HK1145138A1 (en) 2011-04-08
IL212064A (en) 2016-06-30
US20170333411A1 (en) 2017-11-23
PT2343070E (pt) 2015-01-14
AU2009313302B2 (en) 2011-01-06
PT2191831E (pt) 2011-05-24
US8609701B2 (en) 2013-12-17
EP2500019B1 (en) 2016-04-06
SI2191831T1 (sl) 2011-07-29
ZA201102411B (en) 2014-06-25
MX2011004904A (es) 2011-06-16
SV2011003897A (es) 2011-08-09
US20120077850A1 (en) 2012-03-29
PL2343070T3 (pl) 2015-04-30
NI201100091A (es) 2011-11-03
EP2500019A1 (en) 2012-09-19
EP2343070A1 (en) 2011-07-13
DK2191831T3 (da) 2011-06-20
GEP201706719B (en) 2017-08-25
HK1176002A1 (zh) 2013-07-19
HRP20141224T1 (en) 2015-03-27
CY1115862T1 (el) 2017-01-25
KR20110094295A (ko) 2011-08-23
JP2012193193A (ja) 2012-10-11

Similar Documents

Publication Publication Date Title
EP2191831B1 (en) Modifying pirfenidone treatment for patients with atypical liver function
US7566729B1 (en) Modifying pirfenidone treatment for patients with atypical liver function
US10322121B2 (en) Methods of providing weight loss therapy in patients with major depression
EP2601958A1 (en) Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
JP2024533756A (ja) アトゲパントを含む片頭痛の併用療法
US20190314351A1 (en) Pirfenidone treatment for patients with atypical liver function
JP2024538054A (ja) 高シュウ酸尿症及び腎結石の治療のための１ｈ－１，２，３－トリアゾール－４－カルボン酸
KR20240153368A (ko) 암 치료를 위한 이발티노스타트의 용도
AU2012205256A1 (en) Pirfenidone Treatment for Patients with Atypical Liver Function
OA19816A (en) Pirfenidone Treatment For Patients With Atypical Liver Function.
REMS Pirfenidone (ESBRIET®)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1145138

Country of ref document: HK

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602009000986

Country of ref document: DE

Date of ref document: 20110512

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009000986

Country of ref document: DE

Effective date: 20110512

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20110516

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

Ref country code: CH

Ref legal event code: NV

Representative=s name: R. A. EGLI & CO. PATENTANWAELTE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20110478

Country of ref document: HR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20110401163

Country of ref document: GR

Effective date: 20110614

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20110478

Country of ref document: HR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E005427

Country of ref document: EE

Effective date: 20110510

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1145138

Country of ref document: HK

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 9524

Country of ref document: SK

Ref country code: NO

Ref legal event code: T2

Effective date: 20110330

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: HU

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

26N No opposition filed

Effective date: 20120102

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009000986

Country of ref document: DE

Effective date: 20120102

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2387421

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120921

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20151012

Year of fee payment: 7

PLAA Information modified related to event that no opposition was filed

Free format text: ORIGINAL CODE: 0009299DELT

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

R26N No opposition filed (corrected)

Effective date: 20120102

RIN2 Information on inventor provided after grant (corrected)

Inventor name: SZWARCBERG, JAVIER

Inventor name: BRADFORD, WILLIAMSON ZIEGLER

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170602

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20171024

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: EE

Payment date: 20171029

Year of fee payment: 9

Ref country code: MC

Payment date: 20171129

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20171005

Year of fee payment: 9

Ref country code: CY

Payment date: 20171010

Year of fee payment: 9

Ref country code: LV

Payment date: 20171108

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20151008

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161107

REG Reference to a national code

Ref country code: NO

Ref legal event code: CHAD

Owner name: INTERMUNE, US

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20171115

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602009000986

Country of ref document: DE

Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602009000986

Country of ref document: DE

Representative=s name: VKK PATENTANWAELTE PARTG MBB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602009000986

Country of ref document: DE

Owner name: INTERMUNE, INC., SOUTH SAN FRANCISCO, US

Free format text: FORMER OWNER: INTERMUNE, INC., BRISBANE, CALIF., US

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: INTERMUNE, INC., US

Free format text: FORMER OWNER(S): INTERMUNE, INC., US

REG Reference to a national code

Ref country code: LU

Ref legal event code: HC

Owner name: INTERMUNE, INC.; US

Free format text: FORMER OWNER: INTERMUNE INC.

Effective date: 20181003

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E005427

Country of ref document: EE

Effective date: 20181130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181106

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181106

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCOW

Free format text: NEW ADDRESS: C/O GENENTECH, INC. LEGAL DEPARTMENT 1 DNA WAY, SOUTH SAN FRANCISCO, CA 94080-4990 (US)

REG Reference to a national code

Ref country code: GB

Ref legal event code: S29

Free format text: OFFER FILED; APPLICATION FILED 17 JULY 2019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181106

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190531

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCOW

Free format text: NEW ADDRESS: 1 DNA WAY, SOUTH SAN FRANCISCO, CA 94080-4990 (US)

Ref country code: CH

Ref legal event code: PFA

Owner name: INTERMUNE INC., US

Free format text: FORMER OWNER: INTERMUNE, INC., US

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: INTERMUNE, INC.; US

Effective date: 20190920

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20110478

Country of ref document: HR

Payment date: 20191007

Year of fee payment: 11

REG Reference to a national code

Ref country code: GB

Ref legal event code: S29

Free format text: OFFER ACCEPTED

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602009000986

Country of ref document: DE

Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE

REG Reference to a national code

Ref country code: SK

Ref legal event code: TE4A

Ref document number: E 9524

Country of ref document: SK

Owner name: INTERMUNE, INC., SOUTH SAN FRANCISCO, CA, US

Effective date: 20191204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20191106

REG Reference to a national code

Ref country code: DE

Ref legal event code: R008

Ref document number: 602009000986

Country of ref document: DE

Ref country code: DE

Ref legal event code: R039

Ref document number: 602009000986

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181106

REG Reference to a national code

Ref country code: HR

Ref legal event code: PNAN

Ref document number: P20110478

Country of ref document: HR

Owner name: INTERMUNE, INC., US

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20110478

Country of ref document: HR

Payment date: 20201015

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R040

Ref document number: 602009000986

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20110478

Country of ref document: HR

Payment date: 20211105

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20110478

Country of ref document: HR

Payment date: 20221102

Year of fee payment: 14

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230505

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20110478

Country of ref document: HR

Payment date: 20231011

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231016

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20231013

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231012

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231208

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231103

Year of fee payment: 15

Ref country code: SI

Payment date: 20231016

Year of fee payment: 15

Ref country code: SE

Payment date: 20231010

Year of fee payment: 15

Ref country code: RO

Payment date: 20231013

Year of fee payment: 15

Ref country code: PT

Payment date: 20231106

Year of fee payment: 15

Ref country code: NO

Payment date: 20231108

Year of fee payment: 15

Ref country code: LT

Payment date: 20231019

Year of fee payment: 15

Ref country code: IT

Payment date: 20231010

Year of fee payment: 15

Ref country code: IE

Payment date: 20231009

Year of fee payment: 15

Ref country code: HU

Payment date: 20231019

Year of fee payment: 15

Ref country code: HR

Payment date: 20231011

Year of fee payment: 15

Ref country code: FR

Payment date: 20231009

Year of fee payment: 15

Ref country code: FI

Payment date: 20231116

Year of fee payment: 15

Ref country code: DE

Payment date: 20231003

Year of fee payment: 15

Ref country code: CZ

Payment date: 20231018

Year of fee payment: 15

Ref country code: CH

Payment date: 20231202

Year of fee payment: 15

Ref country code: BG

Payment date: 20231016

Year of fee payment: 15

Ref country code: AT

Payment date: 20231025

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231013

Year of fee payment: 15

Ref country code: BE

Payment date: 20231016

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240105

Year of fee payment: 15